On May 6, 2020, bioMerieux announced performance validation and the launch of VIDAS anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV-2 that causes the COVID-19 disease.

Hospitals and private laboratories can run the tests on bioMerieux’s VIDAS analyzers (MINI VIDA, VIDAS and VIDAS 3) which are widely available with more than 30 000 systems installed around the world.